An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program
Open Access
- 8 August 2022
- journal article
- research article
- Published by Wiley in Epilepsia Open
- Vol. 7 (4) , 578-587
Abstract
Objective: To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6‐17, and ≥18 years old, treated in a real‐world setting.Methods: Patients with DS were treated with fenfluramine in the European Union Early Access Program (EAP). Following a 28‐day baseline period to establish the pretreatment monthly convulsive seizure frequency (MCSF), fenfluramine was started at a dose chosen by the treating physician and gradually titrated based on efficacy and tolerability up to a maximum of 0.7 mg/kg/day. Seizure incidence was recorded in a written diary, and adverse events (AEs) were reported at each patient visit. Cardiovascular safety was assessed by transthoracic echocardiography before treatment started and at least every 6 months thereafter.Results: A total of 149 patients have enrolled in the EAP and 63 were <6 years old, 62 were 6‐17 years old, and 24 were ≥18 years old. After 3 months of treatment 62%, 53%, and 50% of patients demonstrated ≥75% reduction in MCSF in the <6, 6‐17, and ≥18‐year‐old groups, respectively. This pattern of response was sustained through 12 months of treatment with 55%, 46%, and 80% of the <6, 6‐17, and ≥18‐year‐old groups, respectively, experiencing a ≥75% reduction in MCSF. Most common AEs were loss of appetite (21%) and somnolence (16%). No valvular heart disease or pulmonary artery hypertension was observed.Significance: The magnitude, consistency, and durability of the response to add‐on fenfluramine is consistent across age groups in patients with Dravet syndrome.Keywords
Funding Information
- Zogenix
This publication has 18 references indexed in Scilit:
- Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive RegimensJAMA Neurology, 2020
- Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literatureEpilepsy & Behavior, 2019
- Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort surveyDevelopmental Medicine & Child Neurology, 2017
- Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient populationCurrent Medical Research and Opinion, 2017
- Mortality in Dravet syndromeEpilepsy Research, 2016
- Mortality in Dravet syndrome: A reviewEpilepsy & Behavior, 2016
- Incidence of Dravet Syndrome in a US PopulationPediatrics, 2015
- The European patient with Dravet syndrome: Results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndromeEpilepsy & Behavior, 2015
- The core Dravet syndrome phenotypeEpilepsia, 2011
- Cognitive side effects of anti-epileptic drugsSeizure: European Journal of Epilepsy, 2006